05:06 AM EDT, 10/22/2026 (MT Newswires) -- Ixico (IXI.L) secured a new contract and an extension worth a combined 1.5 million pounds sterling for neuroimaging in Alzheimer's disease diagnostics. The British neuroscience imaging and biomarker analytics company will manage and analyze neuroimaging for a Phase 2b clinical trial in Alzheimer's for an undisclosed biotechnology company over three years, according to a Thursday release. Ixico also secured a one-year extension to a contract with an international life sciences and diagnostics client for the use of its IXI neuroimaging platform to support validation and regulatory approval of a blood-based biomarker to diagnose Alzheimer's.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.